Is Sarepta Therapeutics (SRPT) overvalued or fairly valued?

MarketChacha shows Sarepta Therapeutics's valuation in context — a trailing P/E of about 46.9, a forward P/E of about 6.5, a price-to-book of about 1.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Sarepta Therapeutics's revenue?

Sarepta Therapeutics reported revenue of $1.9B for FY2025, with net profit of $-713.4M, per official filings.

What is the share price of Sarepta Therapeutics (SRPT)?

Sarepta Therapeutics last traded at $15.95 (-1.6% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Sarepta Therapeutics

SRPT · NYSE · Healthcare · United States

$15.95-1.6%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:33 PM

Snapshot

TickerSRPT

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees835

HeadquartersCambridge, United States

Market cap$1.7B

P/E (TTM)46.9

P/B1.1

Volume1.5M

Websitewww.sarepta.com

Filings tracked3

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Profile as reported by Yahoo Finance.

Who owns it

Insiders4.2%
Institutions95.8%
Public & other0.0%

447 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.13.98%
Vanguard Portfolio Management LLC6.29%
State Street Corporation6.26%
AQR Capital Management, LLC6.09%
Two Sigma Investments, LP4.35%
Vanguard Capital Management LLC4.34%
First Trust Advisors LP3.92%
RA Capital Management, L.P.3.70%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of -62.5% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-46.8% → -38.3%

Margin has expanded by about 8.5 points — the business is getting more profitable.

Return on equity-62.5%

Latest ROE of -62.5% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $370.9M · EPS 0.48

Est. earnings growth +472.8%

Next fiscal year

Rev $1.4B · EPS 2.45

Est. earnings growth -48.9%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$10.4252-wk range$25.32

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.7B

Day change

-1.6%

P/E (TTM)

46.9

Fwd P/E

6.5

P/B

1.1

Beta

0.20

Revenue (FY2025)

$1.9B

Net margin

-38.3%

ROE

-62.5%

Revenue CAGR (2y)

+27.6%

EPS (FY2025)

-7.13

Net profit (FY2025)

$-713.4M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about SRPT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.9B	$-713.4M	-7.13	-38.3%	-62.5%
FY2024	$1.8B	$235.2M	2.34	13.2%	15.4%
FY2023	$1.1B	$-536.0M	-5.80	-46.8%	-62.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$330.5M	$331.0M*	2.88	—
2025Q4	—	$-412.2M	-3.93	—
2025Q3	$370.0M	$-50.6M	-0.50	-13.7%
2025Q2	$513.1M	$196.9M	1.89	38.4%
2025Q1	$611.5M	$-447.5M	-4.60	-73.2%
2024Q4	—	$159.0M	1.50	—
2024Q3	$429.8M	$33.6M	0.34	7.8%
2024Q2	$360.5M	$6.5M	0.07	1.8%
2024Q1	$359.5M	$36.1M	0.37	10.0%
2023Q3	$309.3M	$-40.9M	-0.46	-13.2%
2023Q2	$239.0M	$-23.9M	-0.27	-10.0%
2023Q1	$231.5M	$-516.8M	-5.86	-223.2%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Shareholder vote results, Exhibits
SEC6/4/2026material
10-Q filing
SEC5/6/2026
8-K — Results of operations, Exhibits
SEC5/6/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.